BACKGROUND AND OBJECTIVES: Despite reporting estimated GFR (eGFR), use of evidence-based interventions in CKD remains suboptimal. This study sought to determine the effect of an enhanced eGFR laboratory prompt containing specific management recommendations, compared with standard eGFR reporting in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cluster randomized trial of a standard or enhanced eGFR laboratory prompt was performed in 93 primary care practices in Alberta, Canada. Although all adult patients with CKD (eGFR <60 ml/min per 1.73 m(2)) were included, medication data were only available for elderly patients (aged ≥66 years). The primary outcome, the proportion of patients with diabetes or proteinuria receiving an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), was assessed in elderly CKD patients. RESULTS: There were 5444 elderly CKD patients with diabetes or proteinuria who were eligible for primary outcome assessment, irrespective of baseline ACEi/ARB use. ACEi/ARB use in the subsequent year was 77.1% and 76.9% in the standard and enhanced prompt groups, respectively. In the subgroup of elderly patients with an eGFR <30 ml/min per 1.73 m(2), ACEi/ARB use was higher in the enhanced prompt group. Among 22,092 CKD patients, there was no difference in the likelihood of a composite clinical outcome (death, ESRD, doubling of serum creatinine, or hospitalization for myocardial infarction, heart failure, or stroke) over a median of 2.1 years. CONCLUSIONS: In elderly patients with CKD and an indication for ACEi/ARB, an enhanced laboratory prompt did not increase use of these medications.
RCT Entities:
BACKGROUND AND OBJECTIVES: Despite reporting estimated GFR (eGFR), use of evidence-based interventions in CKD remains suboptimal. This study sought to determine the effect of an enhanced eGFR laboratory prompt containing specific management recommendations, compared with standard eGFR reporting in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cluster randomized trial of a standard or enhanced eGFR laboratory prompt was performed in 93 primary care practices in Alberta, Canada. Although all adult patients with CKD (eGFR <60 ml/min per 1.73 m(2)) were included, medication data were only available for elderly patients (aged ≥66 years). The primary outcome, the proportion of patients with diabetes or proteinuria receiving an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), was assessed in elderly CKDpatients. RESULTS: There were 5444 elderly CKDpatients with diabetes or proteinuria who were eligible for primary outcome assessment, irrespective of baseline ACEi/ARB use. ACEi/ARB use in the subsequent year was 77.1% and 76.9% in the standard and enhanced prompt groups, respectively. In the subgroup of elderly patients with an eGFR <30 ml/min per 1.73 m(2), ACEi/ARB use was higher in the enhanced prompt group. Among 22,092 CKDpatients, there was no difference in the likelihood of a composite clinical outcome (death, ESRD, doubling of serum creatinine, or hospitalization for myocardial infarction, heart failure, or stroke) over a median of 2.1 years. CONCLUSIONS: In elderly patients with CKD and an indication for ACEi/ARB, an enhanced laboratory prompt did not increase use of these medications.
Authors: Finlay A McAlister; Miriam Fradette; Sumit R Majumdar; Randall Williams; Michelle Graham; James McMeekin; William A Ghali; Ross T Tsuyuki; Merril L Knudtson; Jeremy Grimshaw Journal: CMAJ Date: 2009-11-23 Impact factor: 8.262
Authors: Carmen A Peralta; Michael G Shlipak; Suzanne Judd; Mary Cushman; William McClellan; Neil A Zakai; Monika M Safford; Xiao Zhang; Paul Muntner; David Warnock Journal: JAMA Date: 2011-04-11 Impact factor: 56.272
Authors: T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey Journal: Ann Intern Med Date: 2001-07-17 Impact factor: 25.391
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: Hude Quan; Nadia Khan; Brenda R Hemmelgarn; Karen Tu; Guanmin Chen; Norm Campbell; Michael D Hill; William A Ghali; Finlay A McAlister Journal: Hypertension Date: 2009-10-26 Impact factor: 10.190
Authors: Samuel A Silver; Chaim M Bell; Glenn M Chertow; Prakesh S Shah; Kaveh Shojania; Ron Wald; Ziv Harel Journal: Clin J Am Soc Nephrol Date: 2017-09-06 Impact factor: 8.237
Authors: Luigi Tarantini; Giulia Barbati; Giovanni Cioffi; Finlay Aleck McAlister; Justin Adrian Ezekowitz; Carmine Mazzone; Giorgio Faganello; Giulia Russo; Enrico Franceschini Grisolia; Andrea Di Lenarda Journal: Intern Emerg Med Date: 2015-06-30 Impact factor: 3.397
Authors: Kaveh G Shojania; Alison Jennings; Alain Mayhew; Craig R Ramsay; Martin P Eccles; Jeremy Grimshaw Journal: Cochrane Database Syst Rev Date: 2009-07-08
Authors: Nedra S Whitehead; Laurina Williams; Sreelatha Meleth; Sara Kennedy; Nneka Ubaka-Blackmoore; Michael Kanter; Kevin J O'Leary; David Classen; Brian Jackson; Daniel R Murphy; James Nichols; David Stockwell; Thomas Lorey; Paul Epner; Jennifer Taylor; Mark L Graber Journal: J Appl Lab Med Date: 2019-03-11
Authors: Dannielle McBride; Daniel Dohan; Margaret A Handley; Neil R Powe; Delphine S Tuot Journal: Am J Kidney Dis Date: 2013-12-02 Impact factor: 8.860
Authors: Celia C Kamath; Claudia C Dobler; Rozalina G McCoy; Michelle A Lampman; Atieh Pajouhi; Patricia J Erwin; John Matulis; Muhamad Elrashidi; Joseph Darcel; Mouaz Alsawas; Zhen Wang; Nilay D Shah; M Hassan Murad; Bjorg Thorsteinsdottir Journal: J Gen Intern Med Date: 2020-10-26 Impact factor: 5.128